These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 21426372)

  • 1. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.
    Lazaar AL; Sweeney LE; MacDonald AJ; Alexis NE; Chen C; Tal-Singer R
    Br J Clin Pharmacol; 2011 Aug; 72(2):282-93. PubMed ID: 21426372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
    Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
    Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist.
    Nicholson GC; Tennant RC; Carpenter DC; Sarau HM; Kon OM; Barnes PJ; Salmon M; Vessey RS; Tal-Singer R; Hansel TT
    Pulm Pharmacol Ther; 2007; 20(1):52-9. PubMed ID: 16406722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects.
    Miller BE; Mistry S; Smart K; Connolly P; Carpenter DC; Cooray H; Bloomer JC; Tal-Singer R; Lazaar AL
    BMC Pharmacol Toxicol; 2015 Jun; 16():18. PubMed ID: 26092545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.
    Moss RB; Mistry SJ; Konstan MW; Pilewski JM; Kerem E; Tal-Singer R; Lazaar AL;
    J Cyst Fibros; 2013 May; 12(3):241-8. PubMed ID: 22995323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
    Aul R; Patel S; Summerhill S; Kilty I; Plumb J; Singh D
    Int Immunopharmacol; 2012 Jul; 13(3):225-31. PubMed ID: 22561413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways.
    Pignatti P; Moscato G; Casarini S; Delmastro M; Poppa M; Brunetti G; Pisati P; Balbi B
    J Allergy Clin Immunol; 2005 Jan; 115(1):88-94. PubMed ID: 15637552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.
    Leaker BR; Barnes PJ; O'Connor B
    Respir Res; 2013 Dec; 14(1):137. PubMed ID: 24341382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
    Jurcevic S; Humfrey C; Uddin M; Warrington S; Larsson B; Keen C
    Br J Clin Pharmacol; 2015 Dec; 80(6):1324-36. PubMed ID: 26182832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects.
    Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM
    Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1.
    Braber S; Overbeek SA; Koelink PJ; Henricks PA; Zaman GJ; Garssen J; Kraneveld AD; Folkerts G
    Eur J Pharmacol; 2011 Oct; 668(3):443-9. PubMed ID: 21458445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
    Kaur M; Singh D
    J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature.
    Coelho FM; Pinho V; Amaral FA; Sachs D; Costa VV; Rodrigues DH; Vieira AT; Silva TA; Souza DG; Bertini R; Teixeira AL; Teixeira MM
    Arthritis Rheum; 2008 Aug; 58(8):2329-37. PubMed ID: 18668539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice.
    Matzer SP; Zombou J; Sarau HM; Röllinghoff M; Beuscher HU
    Immunobiology; 2004; 209(3):225-33. PubMed ID: 15518334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
    Kirsten AM; Förster K; Radeczky E; Linnhoff A; Balint B; Watz H; Wray H; Salkeld L; Cullberg M; Larsson B
    Pulm Pharmacol Ther; 2015 Apr; 31():36-41. PubMed ID: 25681277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin-1 induces neutrophil recruitment in adaptive inflammation via TNFα and CXCL1/CXCR2 in mice.
    Zarpelon AC; Pinto LG; Cunha TM; Vieira SM; Carregaro V; Souza GR; Silva JS; Ferreira SH; Cunha FQ; Verri WA
    Can J Physiol Pharmacol; 2012 Feb; 90(2):187-99. PubMed ID: 22320712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
    Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
    Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial.
    Nair P; Gaga M; Zervas E; Alagha K; Hargreave FE; O'Byrne PM; Stryszak P; Gann L; Sadeh J; Chanez P;
    Clin Exp Allergy; 2012 Jul; 42(7):1097-103. PubMed ID: 22702508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers.
    Alexis NE; Lay JC; Haczku A; Gong H; Linn W; Hazucha MJ; Harris B; Tal-Singer R; Peden DB
    Environ Health Perspect; 2008 Jun; 116(6):799-805. PubMed ID: 18560537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.